-1.08 (-0.45%)
Products, Strategic Combinations

Amgen, Kyowa Kirin To Jointly Develop, Commercialize KHK4083, A Phase 3-Ready, Potential First-In-Class Treatment For Atopic Dermatitis

Published: 06/01/2021 09:02 GMT
AMGEN Inc. (AMGN) - Amgen and Kyowa Kirin to Jointly Develop and Commercialize Khk4083, a Phase 3-ready, Potential First-in-class Treatment for Atopic Dermatitis.
Kyowa Kirin - Amgen to Lead Development,manufacturing, Commercialization for Khk4083 for All Markets Except Japan Where Kyowa to Retain All Rights.
Kyowa Kirin - Will Co-promote Khk4083 With Amgen in U.S. and Have Opt-in Rights to Co-promote Khk4083 in Certain Other Markets Outside U.S.kyowa Kirin- Amgen to Make $400 Million Up-front Payment to Kyowa and Future Contingent Milestone Payments Potentially Worth Up to an Additional $850 Million.
Kyowa Kirin and Amgen Will Share Global Development Costs, Except in Japan, and U.S. Commercialization Costs.
Amgen Will Consolidate Sales for Khk4083 in All Markets Globally, Except for Japan.